Liraglutide

Liraglutide is a once-daily GLP-1 receptor agonist approved in the United States under different brand names for type 2 diabetes and for chronic weight management. Its trial record includes cardiovascular outcome data, and it shares the gastrointestinal side effect profile of the class.

Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.